Tackling disease at its source
Long non-coding RNAs
Unexplored Therapeutic Target Landscape
~98% of the human genome is composed of non-protein coding regions. This portion of the genome, known as the 'dark genome,' is dynamically active, generating thousands of therapeutically unexplored long non-coding RNAs (lncRNAs).
LncRNAs - the information processing units of disease-driving cell states
LncRNAs regulate disease-associated gene pathways and proteins in response to the environment, triggering a disease-associated cell state.
To identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility.
HAYA's Full-Stack Dark Genome Platform
Proprietary tools to curate, ID, track and drug high-value lncRNA targets
DiscoverHAYATM
LncRNA Target ID
EchoHAYATM
Logic Gate elements within LncRNA
ViewHAYATM
Identify circulating dark genome biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice.
ChemHAYATM
LncRNA Tailored Drug Development Platform
HAYAtlasTM
A unique orthogonal & iterative multi-omic atlas combining public, proprietary and inferred knowledge
- World’s largest and best curated lncRNA database
- Rigorously profiled lncRNAs and dark genome features are disease-, tissue- and cell-specific, and conserved across species
We are reprograming cell-states to treat rare and common diseases
Wisper
Together we can do more
We are passionate and dedicated to our mission. We have a unique and differentiated proprietary platform for reprogramming disease driving cell-states.
Our platform is powerful and versatile, but through partnerships we believe we can do more and help thousands of patients without a current therapeutic option. Partnering with biopharma companies with a given disease or modality expertise is essential to fulfill our mission. Each disease is a unique universe, and each target may require a different approach.
If you are interested in partnering, please:
